Amount of asset acquisition research and development expense in-process.

No definition available.

Name:	roiv_AssetAcquisitionResearchAndDevelopmentExpenseInProcess
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The future milestone to be received from sale of assets.

+ References

No definition available.

+ Details

Name:	roiv_FutureMilestoneToBeReceivedFromSaleOfAssets
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.

+ References

No definition available.

+ Details

Name:	roiv_GainLossOnSaleOfAssets
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of before tax of income (loss) from a disposal group.

+ References

No definition available.

+ Details

Name:	roiv_IncomeLossFromDisposalGroupBeforeIncomeTax
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Litigation Settlement, Contingent Payment Receivable

+ References

No definition available.

+ Details

Name:	roiv_LitigationSettlementContingentPaymentReceivable
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Litigation Settlement, Expected Fixed Payment Receivable

+ References

No definition available.

+ Details

Name:	roiv_LitigationSettlementExpectedFixedPaymentReceivable
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Litigation Settlement, Fixed Payment, Percentage

+ References

No definition available.

+ Details

Name:	roiv_LitigationSettlementFixedPaymentPercentage
Namespace Prefix:	roiv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Litigation Settlement, Number Of Patents

+ References

No definition available.

+ Details

Name:	roiv_LitigationSettlementNumberOfPatents
Namespace Prefix:	roiv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Litigation Settlements Receivable, Current

+ References

No definition available.

+ Details

Name:	roiv_LitigationSettlementsReceivableCurrent
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of milestone payment payable.

+ References

No definition available.

+ Details

Name:	roiv_MilestonePaymentPayable
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage ownership of a subsidiary.

+ References

No definition available.

+ Details

Name:	roiv_OwnershipOfSharesPercentage
Namespace Prefix:	roiv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow associated with the upfront cash payment during the period.

+ References

No definition available.

+ Details

Name:	roiv_UpfrontCashPayment
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of upfront cash payment received for sale of assets.

+ References

No definition available.

+ Details

Name:	roiv_UpfrontCashPaymentReceivedForSaleOfAssets
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_LitigationSettlementGain
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=roiv_ArbutusBiopharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=roiv_GenevantSciencesGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=roiv_RSLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=roiv_GenevantSciencesLtd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=roiv_PulmovantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_TelavantHoldingsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=roiv_RSLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=roiv_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=roiv_RSLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=roiv_RocheTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Recent Transactions and Developments - Narrative (Details) $ in Thousands			1 Months Ended		4 Months Ended	5 Months Ended	8 Months Ended	12 Months Ended
	Mar. 03, 2026 USD ($) patent	Dec. 14, 2023 USD ($)	Aug. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jul. 08, 2026 USD ($)	Mar. 31, 2023 USD ($)	Dec. 14, 2023 USD ($)	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation settlement,contingent payment	$ 1,300,000
Number of patents \| patent	4
Expected allocation of fixed payment receivable	$ 770,200
Gain on litigation settlement								$ 770,235	$ 0	$ 0
Litigation settlement receivable								770,235	0
Legal settlements paid								1,300,000
Gain (loss) on sale of assets								$ 0	110,387	5,348,410
Arbutus
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Settlement value percentage	20.00%
Genevant Sciences GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Settlement value percentage	80.00%
Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation settlement, fixed payment					$ 950,000
RSL \| Genevant Sciences Ltd.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership of subsidiary	83.00%
Arbutus \| Genevant Sciences Ltd.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership of subsidiary	16.00%
Pulmovant
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront cash payment				$ 14,000
Asset acquisition, research and development expense in process										14,000
Pulmovant \| Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Milestone payment payable				$ 280,000
Telavant Holdings, Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pretax loss						$ 101,900	$ 71,100
Telavant Holdings, Inc \| RSL
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership of subsidiary		75.00%					75.00%
Telavant Holdings, Inc \| Pfizer
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership of subsidiary		25.00%					25.00%
Telavant Holdings, Inc \| RSL
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale of assets									$ 110,400	5,300,000
Roche Transaction
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront cash payment		$ 7,100,000					$ 7,100,000				$ 7,100,000
Consideration to be received from milestone		150,000	$ 150,000
Roche Transaction \| RSL
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront cash payment		5,200,000					$ 5,200,000			5,234,373
Consideration to be received from milestone		$ 110,400
Gain (loss) on sale of assets										$ 5,348,410